Session Information
Date: Wednesday, June 7, 2017
Session Title: Parkinson's Disease: Genetics
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: Genetic testing Parkin (PARK 2) gene in patients with young-onset Parkinson’s disease in Belarus.
Background: The diagnosis of young-onset Parkinson’s disease (PD) is the same as idiopathic, or typical, PD except for the age of the patient. Onset usually occurs between ages 20 and 40 years with an average age of onset in the early to mid-thirties. A group of patients who had onset before 40 is very likely to include people with genetic Parkinson’s. PARK2, the gene encoding the protein parkin, is the only gene in which pathogenic variants are known to cause parkin type of early-onset Parkinson disease. The diagnosis of parkin type of early-onset Parkinson disease can only be confirmed when pathogenic variants are identified on both alleles of PARK2 (i.e., the individual is homozygous for the same pathogenic allele or compound heterozygous for two different pathogenic alleles). To date, identified 30 different mutations in this gene, and over 90% of them are located in exons 2, 3, 4 and 7 (“hot” exons), R275W mutation is one of the most frequently detected in European population, N273S mutation has been previously described in one case from France [1].
Methods: Genetic analysis of DNA samples of 22 Parkinson’s disease patients with rigidity, bradykinesia, and resting tremor; 16 of them had family history of Parkinson’s disease. For the study was used DNA from peripheral blood leukocytes by phenol-chloroform extraction method. To identify single-nucleotide substitutions in the gene PARK2 used the method of direct sequencing of the “hot” exons. Large exon deletions and duplications PARK2 gene was performed with the denaturing High Performance Liquid Chromatography (dHPLC). To estimate the amount of PCR product was carried out a comparative analysis of the following combinations of exons: 3/7/12, 2/7/8; 3/8/10, 6/11, 4/5, 3/9, 2/3/4.
Results: Mutations PARK2 gene was found in 4 of 22 patients: 1st patient- two heterozygous single nucleotide substitutions in R275W and N273S; 2nd patient – heterozygous R275W mutation and deletion of exons 3 and 4; 3rd patient – homozygous deletion of exons 3 and 4; 4th patient – heterozygous deletion of exons 3 and 4.
Conclusions: Parkin type of early-onset PD is rare and clinically indistinguishable from idiopathic PD. Detected deletion of PARK2 exons 3 and 4 is possibly dominant type of mutations in Belarus and may be associated with the “founder effect”.
References: [1] Lesage, S. Rare heterozyzous parkin variants in French early-onset Parkinson disease patients and controls / S. Lesage, E. Lohmann, F. Tison // J Med Genet. 2008. 45:43–46.
To cite this abstract in AMA style:
A. Ivashynka, S. Likhachev. Parkin (PARK 2) Mutations in Patients with Early-Onset Parkinson’s Disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/parkin-park-2-mutations-in-patients-with-early-onset-parkinsons-disease/. Accessed December 10, 2024.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/parkin-park-2-mutations-in-patients-with-early-onset-parkinsons-disease/